GlassScriptPhysician profile
Michael M Mccombs
NPI 1194709907
$1,016.25
in general payments reported to CMS, 2019-2025
21 companies · $17.95 in 2025
The $17.95 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $18.52 · 2022: $143 · 2023: $394 · 2024: $443 · 2025: $17.95.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $855.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $854.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $154.68 | 2022-2024 | Xarelto |
| Pfizer INC. | $132.63 | 2021-2025 | |
| Lilly USA, LLC | $89.98 | 2023-2024 | Mounjaro, Zepbound |
| Abbvie INC. | $87.57 | 2022-2024 | |
| Xeris Pharmaceuticals, INC. | $78.54 | 2023-2024 | Gvoke Hypopen |
| Glaxosmithkline, LLC. | $72.61 | 2023-2024 | Trelegy Ellipta, Shingrix, Arexvy |
| Dexcom, INC. | $63.38 | 2024 | Dexcom G6 Transmitter |
| Corium, LLC | $47.96 | 2022-2023 | Azstarys |
| Boehringer Ingelheim Pharmaceuticals, INC. | $45.05 | 2024 | |
| Halozyme INC | $34.83 | 2023 | |
| Idorsia Pharmaceuticals US INC | $32.53 | 2023 | Quviviq |
| Amneal Pharmaceuticals LLC | $31.04 | 2023 | Unithroid |
| Agios Pharmaceuticals, INC. | $24.05 | 2023 | Pyrukynd |
| Novartis Pharmaceuticals Corporation | $17.62 | 2024 | |
| Sumitomo Pharma America, INC. | $16.46 | 2024 | Gemtesa |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $15.56 | 2024 | Gardasil, Capvaxive, Gardasil 9 |
| Acella Pharmaceuticals, LLC | $15.27 | 2024 | NP Thyroid 60 |
| Astrazeneca Pharmaceuticals LP | $14.80 | 2024 | Airsupra |
| Amgen INC. | $14.03 | 2024 | Otezla, Repatha |
| Exact Sciences Corporation | $13.98 | 2024 | Cologuard Collection Kit |
| Phathom Pharmaceuticals, INC. | $13.68 | 2024 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Mccombs listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.